专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3858359B1 COMPOSITION, COMPRISING A THIAMINE DERIVATIVE, FOR PREVENTION OR TREATMENT OF HYPERCORTISOLEMIA 有权
公开(公告)号：EP3858359B1
公开(公告)日：2024-03-06
申请号：EP19864600.2
申请日：2019-09-30
发明人： LEE, In Kyu , JEON, Jae Han , KANG, Hyeon-Ji
IPC分类号： A61K31/51 , A61K31/10 , A61K31/675 , A61P5/38 , A61P9/12 , A61P3/10 , A61P3/04 , A61P5/42 , A23L33/10

2. 发明公开

EP4147706A1 COMPOSITION FOR REGULATING THE NEURO-IMMUNE-ENDOCRINE SYSTEM 审中-实审
公开(公告)号：EP4147706A1
公开(公告)日：2023-03-15
申请号：EP21799462.3
申请日：2021-04-30
申请人： Abou Nehmi Filho, Victor , Pinhata Otoch, José , Pessoa, Ana Flávia Marçal
发明人： Abou Nehmi Filho, Victor , Pinhata Otoch, José , Pessoa, Ana Flávia Marçal
IPC分类号： A61K36/28 , A61K31/716 , A61K31/702 , A61K31/7016 , A61K31/733 , A61P1/16 , A61P37/02 , A61P3/02 , A61P5/38 , A61P39/00 , A61K127/00 , A61K131/00
摘要： The present invention deals with the composition of Betaglucans and Silymarin - Silybum marianum and one or more Bifidogenic Prebiotics, for use as a nutritional supplement, or nutraceutical, or as a prebiotic, aiming to modulate the neuro-immune-endocrine axis, via protection and preservation of the intestinal epithelium and liver. Having as main objective to provide better quality of sleep.
The composition according to the invention comprises the following components:
- 1,3 and 1,6 beta-glucans;
- Silymarin ( Silybum marianum ) , or its natural or synthetic flavonolignans or flavonoids; and
- one or more Bifidogenic Prebiotics.

3. 发明公开

EP3929208A1 HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS 审中-公开
公开(公告)号：EP3929208A1
公开(公告)日：2021-12-29
申请号：EP20207117.1
申请日：2013-04-25
申请人： AMGEN INC. , NOVO NORDISK A/S
发明人： ANDERSEN, Mette Dahl , DANTZLER, Jeff , ARMITAGE, Richard J. , CLARK, Rutilio
IPC分类号： C07K14/28 , C07K14/70 , A61P3/04 , A61P3/10 , A61P5/16 , A61P5/38 , A61P13/12 , A61P17/00 , A61P19/02 , A61P19/06 , A61P21/00 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61P37/06 , A61P43/00
摘要： Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.

4. 发明公开

EP3927345A1 THERAPEUTIC USES OF RELACORILANT, A HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATOR 审中-公开
公开(公告)号：EP3927345A1
公开(公告)日：2021-12-29
申请号：EP20759882.2
申请日：2020-02-21
申请人： Corcept Therapeutics Incorporated
发明人： MORAITIS, Andreas
IPC分类号： A61K31/4745 , A61P5/38

5. 发明授权

EP3574914B1 CORTICOSTEROID COMPOSITIONS 有权转让
公开(公告)号：EP3574914B1
公开(公告)日：2021-12-29
申请号：EP19165329.4
申请日：2008-11-12
发明人： LICALSI, Cynthia , PHILLIPS, Elaine , HILL, Malcolm , DESHMUKH, Hemant , JOHNSON, Keith
IPC分类号： A61K9/06 , A61K9/10 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61K45/06 , A61K31/41 , A61K31/341 , A61K31/4439 , A61K31/58 , A61P1/00 , A61P1/04 , A61P5/44 , A61P1/14 , A61P5/38

6. 发明公开

EP3897589A1 PHARMACEUTICAL FORMULATIONS CONTAINING RELACORILANT, A HETEROARYL-KETONE FUSED AZADECALIN COMPOUND 审中-公开
公开(公告)号：EP3897589A1
公开(公告)日：2021-10-27
申请号：EP19898009.6
申请日：2019-12-18
申请人： Corcept Therapeutics Incorporated
发明人： SCOTT, Ian , LEMONS, Travis , CHIA, Yip-Fong
IPC分类号： A61K9/48 , A61K47/14 , A61K47/10 , A61K31/4745 , A61P5/38

7. 发明公开

EP2463290A4 THIENOOXAZEPINE DERIVATIVE 有权
标题翻译： THIENOXAZEPINDERIVAT
公开(公告)号：EP2463290A4
公开(公告)日：2013-01-02
申请号：EP10806458
申请日：2010-08-03
申请人： TAKEDA PHARMACEUTICAL
发明人： MATSUMOTO TAKAHIRO , NOMURA IZUMI
IPC分类号： C07D498/04 , A61K31/553 , A61P1/00 , A61P1/04 , A61P1/08 , A61P1/10 , A61P1/12 , A61P1/16 , A61P1/18 , A61P3/00 , A61P3/04 , A61P3/10 , A61P5/38 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00
CPC分类号： C07D498/04 , A61K31/553

8. 发明公开

EP2308880A1 TETRACYCLIC COMPOUND 审中-公开
标题翻译： TETRACYCLISCHE VERBINDUNG
公开(公告)号：EP2308880A1
公开(公告)日：2011-04-13
申请号：EP09773568.2
申请日：2009-07-03
申请人： Kyowa Hakko Kirin Co., Ltd.
发明人： YAMAMOTO, Junichiro , MORI, Kiyotoshi , ERA, Tomohiro , NAKASATO, Yoshisuke , UCHIDA, Kenji
IPC分类号： C07D491/044 , A61K31/4162 , A61P1/02 , A61P1/04 , A61P1/16 , A61P1/18 , A61P3/10 , A61P5/14 , A61P5/38 , A61P7/06 , A61P7/10 , A61P9/10 , A61P9/14 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/04 , A61P17/06 , A61P17/08
CPC分类号： C07D491/044 , C07D491/14
摘要： Provided are a tetracyclic compound represented by the formula (I):

[in the formula(I),the formula (A) represents a benzene ring or the like,
X represents CH or a nitrogen atom,
Q represents -O- or the like,
R 1 , R 2 , and R 3 may be the same or different and each represent a hydrogen atom or the like,
1, m, and n each represent an integer from one to the maximum substitutable number of substituents, and
R 4 and R 5 may be the same or different and each represent a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译：提供由式（I）表示的四环化合物：[式（I）中，式（A）表示苯环等，X表示CH或氮原子，Q表示-O-等中，R 1，R 2和R 3可以相同或不同，各自表示氢原子等，1，m，n分别表示1个至最大可取代数的取代基的整数，R 4和 R 5可以相同或不同，各自表示氢原子等]或其药学上可接受的盐等。

9. 发明公开

EP1619203A1 GALECTIN 9-INDUCING FACTOR 审中-公开
标题翻译： GALECTIN 9-INDUZIERENDER FAKTOR
公开(公告)号：EP1619203A1
公开(公告)日：2006-01-25
申请号：EP04730110.6
申请日：2004-04-28
申请人： Galpharma Co., Ltd.
发明人： HIRASHIMA, Mitsuomi , NISHI, Nozomu , YAMAUCHI, Akira , YOSHIDA, Naoko , SEKI, Masako
IPC分类号： C07K14/52 , C12N15/09 , A61K38/22 , A61P5/38 , A61P29/00 , A61P35/00 , A61P37/06 , A61P37/08
CPC分类号： A61K38/1709 , C07K14/4726
摘要： It has been disclosed that Galectin 9, which is a physiologically active substance acting as a lectin, is expressed in various cells and a correlationship is observed between the expression level of galectin 9 and the metastatic ability of tumors. Therefore, it is presumed that galectin 9 would relate to various physiological phenomena. Thus, a substance allowing the control of galectin 9 production and release is expected as exerting an activity of inducing antitumor and/or anti-inflammatory actions, etc. Therefore, it is required to reveal the same. It has been found that a factor inducing the production and release of galectin 9, "galectin 9-inducing factor", is contained in a certain solubilized tumor cell membrane fraction. This factor can be obtained as a concanavalin A-adsorbed fraction and as a concentrated active fraction by fractionation with an ion exchange column packed with Resource Q@, a hydroxyapatite column, etc. Assay reagents, drugs, assays, etc. can be developed by using the galectin 9-inducing activity of this factor.
摘要翻译：已经公开了作为凝集素的生理活性物质的半乳凝素9在各种细胞中表达，并且在半乳凝素9的表达水平与肿瘤的转移能力之间观察到相关性。因此，推测半乳凝素9与各种生理现象有关。因此，预期能够控制半乳凝素9的产生和释放的物质具有诱导抗肿瘤和/或抗炎作用的活性等。因此，需要显示相同的物质。已经发现，诱导半乳凝素9的产生和释放的因子“半乳凝素9诱导因子”被包含在某些溶解的肿瘤细胞膜级分中。可以通过用填充有Resource Q @，羟基磷灰石柱等的离子交换柱进行分级，作为伴刀豆素A吸附级分和作为浓缩的活性级分获得该因子。可以通过以下方法开发测定试剂，药物，测定等：使用该因子的半乳凝素9诱导活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式